Conclusions: HSA is a useful method for detecting uncorrectable dose deviations derived from a clear clinical motivation. As such, it is a promising method for detecting deviations relevant to real-time dosimetry. However, the current number of false alerts is still too high for direct clinical implementation.
Purpose/Objective: Entrance dose in vivo dosimetry (IVD) using diodes is an end-to-end QA procedure that is widely used in conventional radiotherapy treatments. However, in advanced delivery techniques, such as SIB-IMRT, the reliability of this QA procedure is controversial. We developed a reliable QA procedure for breast treatments delivered using a SIB-IMRT technique based on IVD using diodes.
Materials and Methods:
We calibrated 6-12 MV QED diodes (Sun Nuclear) using an emX electrometer (IBA) in terms of entrance dose at SSD = 90 cm and field size = 10 cm x 20 cm (average conditions for IMRT breast treatments). We measured correction factors for distance, field size, obliquity, and MLC transmission. We planned 14 SIB breast treatments using 6MV x-rays and 7-9 sliding window IMRT fields (TPS: Eclipse, algorithm: AAA v8.9; Varian). Determining entrance dose points is challenging due to fluence modulation, and also to patient contour irregularities, beam obliquity and tissue heterogeneities. To minimize these challenges, we calculated all treatment fields at 0º gantry angle, maintaining the SSD, on a regular water phantom. For each field, we recorded entrance dose (at maximum dose depth) at two points: on the central axis and on the region of highest fluence. Treatments were performed using a Clinac 2100C/D equipped with a Millenium 120 MLC and the RPM system (Varian) for respiratory motion management. We placed one diode at each of the aforementioned points on the patients' skin. We assessed clinical uncertainties by placing the diodes at the same position but on a Plastic Water phantom (CIRS), and irradiating them under the conditions used for entrance dose calculations. To ensure positioning accuracy was lower than 0.5 cm, we attached a template which projected a 1 cm square grid at isocenter to the collimator using an add-on. We compared IVD measurements with the calculated entrance doses. Results: The table shows the average difference between measurements and calculations, excluding doses below fixed thresholds. Consistency improved by increasing the threshold because we excluded false positives due to non-significant dose contributions. Although agreement between in-phantom measurements and calculations was excellent, in patients we observed larger differences and variability due to positioning inaccuracies (figure). The table shows the two-fold tolerances which provided >95% of acceptable IVD assessments.
Conclusions: IVD using diodes is a feasible QA procedure for breast treatments delivered using a SIB-IMRT technique. We propose using two diodes per field in high-fluence regions (entrance dose >0.2 Gy). We suggest a two-fold tolerance for IVD assessment (95% confidence limits): a dose difference of 15% for both diodes per field, and an average difference of 3.6% including all measurements per patient. This work was funded by grant Barcelona Board of the Spanish Association Against Cancer (AECC) 2012.
